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Altered epigenetic features in circulating
nucleosomes in idiopathic pulmonary
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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disorder of unknown origin with a highly
variable and unpredictable clinical course. Polymorphisms and environmentally induced epigenetic variations seem to
determine individual susceptibility to the development of lung fibrosis.
Methods: We have studied circulating epitopes on cell-free nucleosomes (cfnucleosomes) in 50 IPF patients. We have
compared untreated IPF (n = 23) with IPF receiving antifibrotic therapy (n = 27) and healthy subjects (HS) (n = 27). We
analyzed serum levels of five cfnucleosomes including bound HMGB1 (nucleosomes adducted to high-mobility growth
protein B1), mH2A1.1 (nucleosomes containing the histone variant mH2A1.1), 5mC (nucleosomes associated
with methylated DNA), and H3K9Ac and H3K27Ac (nucleosomes associated with histone H3 acetylated at
lysine 9 or 27 residue).
Results: Our findings showed that serum levels of bound HMGB1, mH2A1.1, 5mC, H3K9Ac, and H3K27Ac
were significantly lower in IPF patients than in HS (p < 0.001, p < 0.001, p < 0.01, p < 0.001, and p < 0.
0001, respectively). Moreover, we found differences in epigenetic profiles between untreated IPF patients and
those receiving anti-fibrotic therapy with mH2A1.1 and 5mC being significantly lower in untreated than in
treated patients (p < 0.01 and p < 0.05, respectively). Combination of four cfnucleosomes (HMGB1, 5mC,
H3K9Ac, and H3K27Ac) allow to discriminate IPF vs HS with a good coefficient of determination (R2 = 0.681).
The AUC for the ROC curve computed by this logistic regression was 0.93 (p < 0.001) with 91% sensitivity at
80% specificity.
Conclusion: Our observations showed that cfnucleosomes (bound HMGB1, mH2A1.1, 5mC, H3K9Ac, and H3K27Ac)
might have potential as biomarkers for diagnosis and treatment response. These results deserve further validation in
longitudinal cohorts.
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Background
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal
lung disorder of unknown origin with a highly vari-
able and unpredictable clinical course [1–3]. Post-
transcriptional modifications and gene-environment
interactions (e.g., smoking, gastro-oesophageal reflux,
and viral infections) appear to be key factors in IPF
pathophysiology [4–7]. Polymorphisms and environmen-
tally induced epigenetic variations seem to be implicated
in individual susceptibility to fibrosis development and
disease progression [8]. Profound phenotype changes
occur in the lung; hence, alveolar epithelial cells become
hyperplasic and potentially mesenchymal cells while fibro-
blasts present myofibroblast characteristics. Differential
expression patterns of mRNA and microRNA (correlated
with epigenetic modifications) have been observed in IPF
compared to healthy subjects (HS) [9]. This suggests that
epigenetic marks may be mediators of environmental
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exposure effects in genetically predisposed individuals and
may lead to the transcriptional changes that occur in IPF
[8]. Although little is known about epigenetic alterations
in IPF [4, 10], experimental evidence has shifted the
pathophysiological paradigm from chronic inflammation
towards abnormal epithelial wound repair with repeated
epigenetic mutational challenge [4].
Nucleosomes are the basic unit of chromatin consist-
ing in a 147-bp DNA strand wrapped around a core of
eight histone protein cores. During cellular damage such
as apoptosis or necrosis, chromatin is fragmented into
oligo- or mono-nucleosomes which are released into the
blood stream [11, 12]. During the last decade, cfnucleo-
somes have appeared as novel non-invasive biomarkers
that could inform on disease potential progression.
However, the level of cfnucleosomes itself may not have
optimal diagnostic value, due to their non-specific
release as it may occur in cancer and acute and chronic
non-malignant inflammatory conditions [13]. Nonethe-
less, specific epigenetic changes could be more inform-
ative. Histone and DNA are both subjected to epigenetic
modifications. Epigenetic nucleosome modifications in-
cluding histone acetylation, histone methylation, or
DNA methylation play fundamental roles in gene regula-
tion and expression [14]. Histone acetylation reduces the
affinity between histones and DNA, thereby facilitating
gene transcription. Histone methylation or DNA methy-
lation has been mostly associated with a repression of
gene transcription even if activation has also been de-
scribed. In addition, nucleosome can be associated with
adduct proteins such as high-mobility group protein 1, a
protein involved in inflammation and in pulmonary fi-
brosis [15]. As a new approach for diagnosis and
monitoring of IPF, we have studied the relevance of
some nucleosome epigenetic features including his-
tone and DNA modifications as well as histone vari-
ants or nucleosome adducts in serum samples of
treated and untreated IPF patients.
Methods
Subject characteristics
Patients were recruited from the ambulatory care poly-
clinics of both Liège University Hospital and Erasme
University Hospital (Brussels). Patients were divided into
two groups: patients with untreated IPF (n = 23) and
patients with treated IPF (n = 27: 18 treated with pirfeni-
done: 9.9±7.4 months; 9 treated with nintedanib: 14.3
±15.8 months (mean ± SD)). The diagnosis of (definite)
IPF was made according to the international recommen-
dations of the ATS [1] using the respiratory function
test, HRCT scan (probable UIP pattern), bronchoalveolar
lavage (when available), as well as the clinical history of
the patient. All other causes of interstitial lung disease
(such pneumoconiosis, hypersensitivity pneumonitis,
pneumonia associated with connective tissue disease, or
drug-induced interstitial lung disease) were excluded.
Diagnosis was based on the combination of the above
results. All cases were discussed by an interstitial lung
disease multidisciplinary group of pulmonologists, rheu-
matologists, radiologists, pathologists, and occupational
medicine and pulmonary rehabilitation specialists. Six-
teen patients underwent a surgical biopsy and seven
patients trans-bronchial cryobiopsies. Twenty-seven
patients were treated with a specific treatment of IPF
(pirfenidone (n = 18) or nintedanib (n = 9)). HS were
recruited from Liège university hospital by advertising
in the waiting room. None showed any symptoms of
a respiratory disease, and all had normal spirometric
values with predicted forced expired volume in one
second (FEV1) > 80% and FEV1/FVC ratio > 70%. Pa-
tients treated with histone deacetylase activators like
theophylline were also excluded.
The protocol was approved by the ethics committee of
CHU of Liège, and all subjects gave written consent be-
fore their enrolment (Belgian number: B707201422832;
ref.: 2014/302).
Cell-free circulating nucleosome measurements
Venous blood was collected at enrolment in Vacutainer
tubes (for serum sampling) from an antecubital site. Ten
nucleosome epitopes, corresponding to nucleosomes as-
sociated methylated DNA (5-methylcytosine (5mC)); nu-
cleosomes associated with histone modifications H3K9Ac,
H3K27Ac, H4PanAc, H3K9me3, H4K20me3, H3K4Me2,
or pH2AX; nucleosomes containing the histone variant
mH2A1.1; and nucleosomes adducted to high-mobility
growth protein B1 (HMGB1), were analyzed in the serum
of IPF patients and controls.
Epitopes on cfnucleosome levels were measured using
Nu.Q™ enzyme-linked immunosorbent assays (ELISA)
(Belgian Volition SPRL, Namur, Belgium) performed
according to the manufacturer’s instructions [16, 17]. In
brief, serum samples (10 μl in duplicate) were incubated
for 2 h 30 min at room temperature in a 96-well micro-
titer plate coated with a monoclonal anti-nucleosome
antibody. After washing steps, the level of cfnucleosomes
containing particular epigenetic feature were quantified
by adding into the well a biotinylated detection anti-
bodies directed to specific epigenetic feature of the nucle-
osomes under investigation (incubation 90 min at room
temperature). The wells were washed and streptavidin-
horseradish peroxidase (HRP) was added. After incubation
for 30 min at room temperature, the wells were washed
and a peroxidase substrate-2,2′-azino-bis-(3-ethylben-
zothiazolonine-6 sulfonic acid) was added. The optical
densities of the wells were read with an X-Mark Micro-
plate spectrophotometer (BioRad).
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Statistical analysis
All the statistical analyses were performed with the
SPSS Statistics 24 software (IBM). For the different
clinical groups, the mean value of duplicate measure-
ments was used. Samples with a coefficient of vari-
ation (%CV) above 20% between its duplicates were
repeated. The mean values were taken into consider-
ation for the statistical analysis only if it reached the
criteria: CV < 20. The distribution of the marker
levels is given as median, interquartile, and total
ranges. Comparisons of cfnucleosomes between the
groups were performed by Kruskall-Wallis followed
by Mann-Whitney U test in case of statistical signifi-
cances. Area under the receiver operating characteristic
(ROC) curves and sensitivities at defined specificities were
calculated to test the performance of the biomarkers for
differential diagnosis. Binary multiple logistic regressions
were used to validate the statistical significance of the
cfnucleosome biomarkers and to evaluate their capacity to
predict disease. p values < 0.05 were considered as statisti-
cally significant.
Results
Subject demographic and functional characteristics
The demographic functional and treatment characteris-
tics are given in Table 1. The average age of IPF patients
was 72 ± 11 years for untreated patients vs 68 ± 9 years
for treated patients. Spirometric values were moderately
lower and comparable in both the treated and untreated
IPF while diffusion lung capacity for CO (DLCO) was
sharply reduced in both IPF groups.
Circulating cell-free nucleosomes
Epigenetic profiles of cfnucleosomes in subjects with un-
treated IPF, treated IPF, or HS were investigated using
ELISA-based Nu.Q™ assays. Ten epigenetic features of
serum cfnucleosomes were analyzed. The receiver oper-
ator characteristic (ROC) curves for each nucleosome
assay in the untreated IPF group vs HS were established
(data not shown). The area under the curve (AUC) for
the individual ROC curves varied from 0.54 to 0.85
(Table 2).
Of note, diagnostic sensitivity at 80% specificity for the
five best nucleosome biomarkers ranged from 61 to 86%
(Table 2). Remarkably, the level of these five cfnucleo-
some features, namely, HMGB1, mH2A1.1, 5mC,
H3K9Ac, and H3K27Ac were significantly lower in
untreated IPF than in HS (Fig. 1). Box plots derived from
the best five individual assays based on the AUC are
shown in Fig. 1.
Interestingly, 5mC and mH2A1 levels allowed to dis-
criminate between untreated and treated IPF patients
(p < 0.05 and p < 0.01, respectively) (Fig. 1). Remarkably,
in our study, specific anti-fibrotic therapies significantly
modified these two markers in treated IPF patients
bringing them close to HS values (Fig. 1).







Age, years 60(9) 72(11)** 68(9)*
Gender (M/F) 14/13 20/3 19/8
Height, cm 170(9) 171(10) 170(9)
Weight, kg 74(12) 76(15) 78(10)
BMI, kg/m2 26(3) 26(4) 27(3)
Smokers (NS/FS/S) 6/17/4 6/13/4 7/20/0
FEV1 post-BD, %pred. 104(14) 75(14)*** 67(13)***
FVC post-BD, %pred. 112(20) 74(14)*** 66(16)***
FEV1/FVC post-BD, % 78(5) 78(11) 80(6)
TLC, %pred. nd 70(13) 68(15)
RV, %pred. nd 71(32) 82(27)
DLCO, %pred. nd 39(13) 38(13)
KCO, %pred. nd 62(13) 70(20)
ICS (yes/no) 0/27 1/22 0/27
OCS (yes/no) 0/27 0/23 0/27
Treatment with pirfenidone/nintedanib nd nd 18/9
Data are expressed as mean (SD)
nd not determined, NS non-smoker, FS former smoker, S smoker, FEV1 forced expired volume in one second, FVC forced vital capacity, TLC total lung capacity,
DLCO diffusion lung capacity for CO, KCO DLCO/alveolar ventilation, ICS inhaled corticosteroids, OCS oral corticosteroids
*p < 0.05, **p < 0.001, ***p < 0.0001 compared to healthy subjects
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Correlation studies between lung function indices and
cfnucleosomes showed a positive correlation between
DLCO/VA (%pred) and H3K27Ac or H3K9Ac (r = 0.313,
p = 0.049; r = 0.341, p = 0.032, respectively).
In addition, we assessed if an increase in the diagnostic
value could be observed by combining levels of cfnucleo-
some modifications. Statistical significance was calculated
for several combinations using binary logistic regressions
and the best combination was selected. This study revealed
a highly statistically significant (p < 0.001) combination
of four cfnucleosomes: HMGB1, 5mC, H3K9Ac, and
H3K27Ac with good coefficient of determination
(R2 = 0.681). In this combination, each individual
predictor was already highly statistically significant. The
AUC for the ROC curve computed by this logistic re-
gression was 0.93 (p < 0.001) with 91% sensitivity at
80% specificity for the discrimination of IPF patients
vs HS (Fig. 2). We also notice that this analysis was gender
independent (all p values > 0.1). Pearson correlation
analysis between age and levels of cfnucleosome
modifications showed only a marginal correlation between
the two parameters (r coefficient of 0.299, 0.330, 0.210,
0.265, and 0.281 for HMGB1, 5mC, H3K9Ac, H3K27Ac,
and mH2A1.1, respectively).
Discussion
We have investigated the clinical diagnostic accuracy for
IPF using ELISA tests for epigenetic epitope variation in
cfnucleosomes in small volumes of serum as a readily
available and non-invasive sample type.
Our finding showed a reduced level of cfnucleosomes
associated with HMGB1. HMGB1 is loosely bound to
the chromatin during interphase and mitosis and has a
rapid turnover between its chromatin-bound and soluble
states. On the contrary, hyperacetylation occurring in
apoptosis favors its chromatin-bound state, thereby pre-
venting HMGB1 release [17]. Although HMGB1 impli-
cation in inflammation and tissue repair has been well
described, its role in IPF seems to be complex and need
further elucidation [18].
Our results showed lower circulating chromatin-
bound HMGB1 in IPF than in normal subjects. This
suggests increase HMGB1 tendency towards its soluble
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cfnucleosome features between healthy subject (n = 27) and untreated
(n = 23) idiopathic pulmonary fibrosis patients. The receiver operator
characteristic (ROC) curve analysis is calculated at 80% specificity. All serum
nucleosome modifications were analyzed by ELISA Nu.Q™ assays
AUC area under the curve
Fig. 1 Serum cfnucleosome modifications in IPF. Discrimination of five Nu.Q™ assays for untreated IPF (n = 23), treated IPF (n = 27), and healthy
subjects (HS) (n = 27). Treatment is pirfenidone (n = 18) and nintedanib (n = 9). Nu.Q™ assays were performed from serum samples. Significant
separation between the untreated IPF and healthy controls was achieved with pre-processed ELISA data from the five cfnucleosome biomarkers.
Significant discrimination between the treated and untreated patients was achieved from the two cfnucleosome biomarkers. p values were determined
by the Mann-Whitney U test. Box plots indicate the median and 25th and 75th percentiles. Whiskers indicate the 10 and 90% percentiles and dot values
falling outside the 10th and 90th percentiles. IPF idiopathic pulmonary fibrosis, OD optical density
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form in IPF as it has been previously described [15].
Therefore, extracellular HMGB1 in IPF could play a pro-
tective role in preventing abundant release of nucleo-
somes as it was previously described during apoptosis
and repair process in lung remodeling [19].
Recent data have shown high histone deacytelase activ-
ity in fibroblasts and myofibroblasts from patients with
IPF [20, 21]. Our results are in agreement with that find-
ing since we found lower levels of histone H3 acetylated
markers (H3K9Ac and H3K27Ac) in untreated IPF pa-
tients. Interestingly, in the current study, patients treated
with anti-fibrotic drugs display cfnucleosome epitope
profile comparable to HS, which suggests that these
drugs may partially restore normal levels of histone H3
acetylation. Moreover, there is a positive correlation be-
tween hypoacetylation and the severity of the disease
assessed by the DLCO/VA quotient, which is known to
be a good marker of the alveolo-capillar membrane
function. However, this correlation is not very strong
and has to be confirmed in a larger prospective study.
Acetylation homeostasis in nucleosomes is the result
of a fine equilibrium between histone acetyl transferases
(HAT) and histone deacetylases (HDAC). Disruption of
this balance either by an increase of HDAC or a de-
crease of HAT or both has been claimed to be involved
in the pathophysiologic process of IPF [15]. Given that
increased acetylation by HDAC inhibition reduces colla-
gen production in different fibroblast types, new anti-
fibrotic drug (suberoylanilide hydroxamic acid) acting as
a histone deacetylase inhibitor (HDACi) appeared to be
a promising therapeutic option in IPF by reducing colla-
gen deposition [22, 23].
Methylation is known to be deregulated in IPF [9].
IPF-associated differentially methylated regions occurred
primarily in promoter regions of genes involved in
biological processes such as cellular assembly and
organization, cellular growth and proliferation, gene
expression, and cell death. All of these processes are re-
ported to be implicated in IPF pathogenesis [9]. Our study
also highlighted that the level of cfnucleosome associated
methylated DNA (5-methylcytosine) is significantly
reduced in untreated IPF compared to HS. Moreover,
specific anti-fibrotic therapies restore 5mC to levels closed
to those seen in HS. Therefore, nucleosome-associated
5mC could potentially be useful for therapeutic monitoring
or prognostic factor to treatment response.
Likewise, we identified a significant reduction in the
level of the cfnucleosome carrying the histone variant
mH2A1.1 in untreated IPF while those patients receiving















Fig. 2 A model with four cfnucleosome biomarkers discriminates IPF vs healthy patients. ROC curve for the discrimination of untreated IPF vs
healthy subjects. The AUC for a model of four cfnucleosome biomarkers (HMGB1, 5mC, H3K9Ac, H3K27Ac) reached 0.928 (p < 0.001) with a sensitivity
of 91% at 80% specificity
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Thinking beyond a single biomarker, we have assessed
the value of combining several cfnucleosome modifica-
tions. After performing specific logistic regression com-
paring HS to untreated IPF, we found that a model of
four Nu.Q™ cfnucleosome biomarkers (5mC, HMGB1,
H3K27ac, and H3K9ac), reached an AUC of 0.93 in a
ROC curve analysis (80% specificity and 91% sensitivity),
which holds promise for use in clinical practice.
Conclusions
In conclusion, we have identified new blood-based cfnu-
cleosome markers in untreated IPF patients. Intriguingly,
some of those biomarkers tend to normalize in the pa-
tients receiving anti-fibrotic treatment. We believe these
cfnucleosomes may have potential as diagnostic and
treatment response tools. This observation warrants fur-
ther validation in larger longitudinal cohorts to confirm
their value as biomarkers in IPF.
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